2024
Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy
Han R, Rao X, Zhou H, Lu L. Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy. International Journal Of Nanomedicine 2024, 19: 4803-4834. PMID: 38828205, PMCID: PMC11144010, DOI: 10.2147/ijn.s461289.Peer-Reviewed Original ResearchConceptsRegulate PD-L1 expressionPD-L1 expressionPD-1/PD-L1Inhibition therapySensitive to immune checkpoint inhibitorsEfficacy of cancer immunotherapyPD-1/PD-L1 inhibitorsImmune checkpoint inhibitorsAnti-cancer immunityEfficacy of monotherapyExploration of combination strategiesModulate immune responsesMRNA vaccine technologyCheckpoint inhibitorsCancer immunotherapyRNA-based therapiesTreatment strategiesImmunomodulatory effectsCancer therapyImmune responseTherapyCancer treatmentVaccine technologyCombination strategiesCancer
2023
Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment
Han R, Wang Y, Lu L. Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment. Pharmaceutics 2023, 16: 59. PMID: 38258070, PMCID: PMC10821464, DOI: 10.3390/pharmaceutics16010059.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsMRNA vaccinesCheckpoint inhibitorsHCC treatmentEffectiveness of mRNAMRNA cancer vaccinesNovel mRNA vaccineSuppressive tumor microenvironmentHepatocellular carcinoma patientsCancer-associated antigensInnovative therapeutic strategiesCOVID-19 preventionCarcinoma patientsVaccine delivery vehiclesCancer vaccinesClinical evidenceHCC preventionTherapeutic strategiesVaccineTumor microenvironmentCancer treatmentPotential targetNew hopeTreatmentTrialsEnhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
Han R, Ling C, Wang Y, Lu L. Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition. Cancer Cell International 2023, 23: 203. PMID: 37716965, PMCID: PMC10504701, DOI: 10.1186/s12935-023-03051-0.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsHepatocellular carcinomaCheckpoint inhibitorsHCC treatmentPD-1/PD-L1 inhibitionPD-1/PD-L1 inhibitorsHDAC2 inhibitorsTreatment of HCCPD-L1 inhibitionAnti-cancer immunityPD-L1 inhibitorsAnti-tumor efficacyNew combination strategiesPD-L1Clinical benefitHigh morbidityTherapeutic effectSolid cancersEffective treatmentLatest evidenceNuclear translocationTreatmentInhibitorsCombination strategiesEfficacyPotential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors
Wang Y, Lu L, Ling C, Zhang P, Han R. Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors. Nutrients 2023, 15: 3984. PMID: 37764768, PMCID: PMC10537481, DOI: 10.3390/nu15183984.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsPD-1/PD-L1 inhibitorsPD-L1 inhibitorsICI therapyDietary interventionBC patientsBreast cancerTherapeutic strategiesNovel immune checkpoint inhibitorsHDAC2 inhibitorsIntegrated therapeutic strategiesOptimal clinical benefitKaplan-Meier plotter platformNew therapeutic strategiesAnti-cancer effectsCheckpoint inhibitorsSupportive therapyClinical benefitHigh morbidityCombination therapyTreatment outcomesLethal malignancyTherapeutic effectEffective treatmentPrognostic analysisCAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
Han R, Li J, Hony J, Xiao Z, wang J, Yao M, Liang S, Lu L. CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment. Frontiers In Immunology 2023, 14: 1052657. PMID: 37006233, PMCID: PMC10061011, DOI: 10.3389/fimmu.2023.1052657.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsC motif chemokine ligand 8Hepatocellular carcinomaCheckpoint inhibitorsDeath ligand 1 (PD-L1) immunotherapyCell death protein 1Treatment of HCCDeath protein 1Chemokine ligand 8Function of monocytesTumor immunosuppression microenvironmentClinical benefitCombination therapyImmunosuppression microenvironmentLethal malignancyTherapeutic effectEffective treatmentHCC treatmentAdvanced stageProtein 1Ligand 8ImmunotherapyTreatmentXII inhibitorsAnticancer drugsMicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment
Zhou H, Jia W, Lu L, Han R. MicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment. Cancers 2023, 15: 824. PMID: 36765782, PMCID: PMC9913694, DOI: 10.3390/cancers15030824.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune checkpoint blockadeBreast cancerCheckpoint inhibitorsCheckpoint moleculesImmune checkpointsImmune checkpoint moleculesCancer-associated mortalityBreast cancer treatmentCommon cancer typesCombination regimenAdverse eventsCheckpoint blockadeClinical benefitTherapeutic effectTherapeutic candidateTherapeutic potentialCancer typesCancerCancer treatmentApplication of miRNAsTargetScan databaseMiRNA therapyTreatmentInhibitors
2020
Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors
Yao L, Jia G, Lu L, Bao Y, Ma W. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. International Immunopharmacology 2020, 85: 106628. PMID: 32474388, DOI: 10.1016/j.intimp.2020.106628.Peer-Reviewed Original ResearchConceptsImmune-related adverse effectsImmune checkpoint inhibitorsICI therapyCheckpoint inhibitorsCancer patientsPredictive biomarkersTumor respondersAnti-PD-1/PD-L1 immunotherapyCell death protein 1 (PD-1) pathwayT-lymphocyte-associated antigen 4PD-L1 immunotherapyVariety of malignanciesAdvanced human cancersConventional anticancer therapiesDegree of severityProtein 1 pathwayNew potential mechanismAntigen-4Cancer immunotherapyToxicity profileImmunotherapyTherapyPatientsAdverse effectsAnticancer therapy